Sun Pharmaceuticals’ stock price advanced 1.15% to Rs 1,129, a day after the company reported the profit of second quarter of FY24 at Rs 2375.51 crore, up 5% in comparison to Rs 2,262.22 crore during the second quarter of FY23, beating estimates. It posted revenue from operations at Rs 12,192.41 crore, up 11.3% as against Rs 10,952.28 crore during the quarter ended September 2022. The company’s EBITDA stood at Rs 3179 crore during the quarter and EBITDA margin for Q2 was at 26.1% vs 27% for Q2 last year.
The share price of Sun Pharmaceuticals gained 1.48% in the last five days, while it dropped 1.13% in the last one month. It has, however, delivered positive returns of 16% in the last six months and 13.25% year to date.
Also Read
Stocks to watch… Read more